ClinicalTrials.gg
CompletedNCT00653549Updated Jun 17, 2011

Bioavailability Study of Torsemide Tablets Under Fasting Conditions

A Phase 1 interventional study of Torsemide and Demadex in To Determine Bioequivalence Under Fasting Conditions, sponsored by Par Pharmaceutical, Inc.. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-17.

Sponsored by Par Pharmaceutical, Inc. (part of Par Health) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Fasting by Par Health — none open to participants now, none under way, none of them phase 3. Fasting · Par Health.

Enrollment
15th of 19
26 · median 32
Started
2001
with 1 other
Phase 1
18 of 19
none open now
Registered
1st of 19
by date

Among the 19 studies in Fasting by Par Health, this one is the 15th largest by enrollment, is one of 2 that started in 2001, is one of 18 in phase 1, and was the 1st registered.

Fasting

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

Browse Fasting studies →

Open to participants now

None of the 19 studies in Fasting by Par Health is open now. The open studies under Fasting, anywhere →

Where they have run

Who these studies take

Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Fasting by Par Health as a file.
02

Study summary

To compare the single-dose bioavailability of Torsemide tablets with Demadex

Read the detailed description

To compare the single -dose bioavailability of Par Torsemide tablets 20mg with that Roche Demadex 1*20mg tablets under fasting conditions.

03

Conditions studied

  • To Determine Bioequivalence Under Fasting Conditions

Browse trials for

Keywords

  • Bioequivalence
  • Torsemide Tablets
  • fasting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects enrolled in the study will be members of the community at large.

  • The Recruitment will be done by radio, newspapers and Anapharm Inc.
  • Anapharm Website advertisements.
  • Subjects must meet all the following criteria in order to be included in the study.
  • Subjects will be male and / or female, smokers and non-smokers, 18 years of age and older.
  • Subjects should read, sign, and date an form prior to the study procedures.
  • Subjects must complete all screening procedures within 28 days prior to the administration of the study medication.

Exclusion criteria

Exclusion Criteria:

  • Breast- feeding female subjects.
  • Any abnormality found during medical screening.
  • Subjects with ≥30
  • Any Clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases) or unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), susceptible of interfering with the absorption of drugs.
  • Clinically significant illness within 4 weeks prior to the administration of the study medication
  • Abnormal laboratory tests judged clinically significant.
  • abnormalities (clinically significant) (PR interval greater than 225ms);or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 60 or over 95 mmHg, or heart rate less than 60 bpm) at screening.
  • History of allergic reactions to torsemide or sulfonylureas (e.g. tolbutamide, chlorpropamide, glyburide and gliclazide) or other related drugs ( e.g. furosemide, bumetanide, sulfabenzamide, sulfacetamide, sulfathiazole, sulfadiazine, sulfamethoxazole, sulfasalazine, sulfisoxazole and dapsone).
  • Any food allergy, intolerance, restriction or special diet that, in the opinion of the Medical Sub- Investigator, could contraindicate the subject's participation in this study.
  • Positive urine drug screen at screening.
  • Positive testing for , , or at screening.
  • Positive urine pregnancy test at screening.(performed on all female subjects)
  • Use of an drug or participation in an investigational study within 30 days prior to administration of the study medication.
  • Donation of plasma ( 500 mL) within 7 days or donation of significant loss of whole blood (450 mL) within 56 days prior to administration of the study medication.
  • History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day (1 Unit = 150 mL of wine or 360 mL of beer or 45 ml of alcohol 40%)
  • History of drug abuse or use of illegal drugs: Use of soft drugs (such as marijuana, pot) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year of the screening visit.
  • Subjects who have taken prescription medication within 14 days prior to administration of study medication or over the counter products within 7 days prior to administration of study medication, except for topical products without systemic absorption.
  • Female subjects of having unprotected sexual intercourse with any non- sterile male partner (i.e. male who has not been sterilized by vasectomy for al least 6 months) within 14 days prior to study drug administration. The Acceptable methods of are :
  • Condom+ spermicide (within 14 days prior to study drug administration)
  • Diaphragm + spermicide (within 14 days prior to study drug administration.
  • Intrauterine contraceptive device (place al least 4 weeks prior to study drug administration)
  • Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication.
  • (examples of inducers: barbiturates, carbamazepine, phenytoin,, rifampin,rifabutin; examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine)
  • Subjects who have undergone clinically significant surgery within 4 weeks prior to the administration of the study medication.
  • Any reason which, in the opinion of the investigator, would Prevent the subject from participating in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    A

    Subjects received Par formulated product under fasting conditions

    Drug: Torsemide

  • Active comparator
    B

    Subjects received Roche formulated product under fasting conditions

    Drug: Demadex

Interventions

  • Tablets, 20 mg, single-dose

    Also known as: Demadex

  • tablets, 20 mg, single-dose

    Also known as: Torsemide

06

What researchers measure

Primary outcomes

  1. Rate and Extend of Absorption

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001, a primary completion of May 2001 and a completion of May 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 7, 2008
Start
Apr 2001
Primary completionActual
May 2001
CompletionActual
May 2001
Last update
Jun 17, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00653549
Collaborators
Anapharm
First posted
Apr 7, 2008
Start date
Apr 2001
Primary completion
May 2001
Completion
May 2001
Last update
Jun 17, 2011

Study contacts

Eric Masson
principal investigator · Anapharm

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Torsemide

Start the discussion